← VRCA
VRCA— Verrica Pharmaceuticals Inc.
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Total revenue | $20.3M+1945.6% | $992K+112.9% | $466K |
| Cost of product revenue | $2.2M+18.3% | $1.9M+541.2% | $289K |
| Cost of license and collaboration revenue | $1.2M+40.8% | $887K | — |
| Selling, general and administrative | $35.2M-40.1% | $58.8M+24.3% | $47.3M |
| Research and development | $8.9M-25.2% | $11.8M-41.7% | $20.3M |
| Loss on disposal of equipment | $246K+196.4% | $83K-96.7% | $2.5M |
| Total operating expenses | $47.8M-35.0% | $73.5M+3.7% | $70.9M |
| Loss from operations | -$12.2M+81.5% | -$65.9M-0.2% | -$65.8M |
| Interest income | $929K-34.4% | $1.4M-48.3% | $2.7M |
| Interest expense | -$7.7M+17.7% | -$9.4M-137.6% | -$4.0M |
| Change in fair value of derivative liability | $2.6M+200.0% | -$2.6M | $0 |
| Loss on extinguishment of debt | -$1.5M | $0 | — |
| Other expense | -$3K+82.4% | -$17K-21.4% | -$14K |
| Total other expense, net | -$5.7M+46.5% | -$10.7M-762.5% | -$1.2M |
| Net loss | -$17.9M+76.6% | -$76.6M-14.3% | -$67.0M |
| Net loss per share, basic (in shares) | -$2K+88.6% | -$15K-898.6% | -$1K |
| Net loss per share, diluted (in shares) | -$2K+88.6% | -$15K-898.6% | -$1K |
| Weighted-average common shares outstanding, basic (in dollars per share) | $10.65B+105.6% | $5.18B-88.6% | $45.34B |
| Weighted-average common shares outstanding, diluted (in dollars per share) | $10.65B+105.6% | $5.18B-88.6% | $45.34B |
| Product revenue, net | |||
| License and collaboration revenue | |||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.